No price history available.

Not enough data to calculate KvantraRank

Based on consensus from external analysts. Not Kvantra's opinion.

BTC Health Limited operates as a Pooled Development Fund, overseen by LHC Capital Partners Pty Ltd. The fund strategically deploys capital across various corporate development stages, from initial seed and startup funding to early, mid, and late-stage venture growth, and into emerging and established growth companies. Its investment focus lies primarily within the healthcare and biotechnology industries, with a specific emphasis on groundbreaking areas such as post-genomics, which encompasses functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. It also targets stem cell biology, particularly stem cell therapies. Other key areas of interest include convergent technologies, like biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics; silicon biology, involving structure-based drug design, virtual screening, computational library design, and in silico ADME/tox; and nanomedicine. The fund exclusively supports businesses located in Australia, investing in both publicly traded and privately held enterprises.

• Intensity Therapeutics, Inc.
• NextCell Pharma AB
• CEL-SCI Corporation
• Chemomab Therapeutics Ltd.
• Kiora Pharmaceuticals, Inc.
• Xcell Therapeutics, Inc.
• VistaGen Therapeutics, Inc.
• Pharmala Biotech Holdings Inc.